PDT

KNOWLEDGE24 | Aavenir to Showcase Generative AI Capabilities for Contract Management on ServiceNow

Retrieved on: 
Thursday, April 25, 2024
ServiceNow, Risk, AI, PDT, Convention center, Synthetic media, Expo, Canon PowerShot Pro1, Generative, Contract management, Organization, Medical device

SANTA CLARA, Calif., April 25, 2024 /PRNewswire/ --  Aavenir, a global AI-Powered Source-to-Pay and Contract Lifecycle Management solutions provider on ServiceNow Platform announces its participation in ServiceNow Knowledge24 event as a Gold Sponsor. The 3-day annual event, held at The Venetian Expo and Convention Center, Las Vegas, Nevada, from May 7-9, 2024, will showcase Aavenir's Generative AI capabilities in Contract Management.   

Key Points: 
  • Aavenir, a ServiceNow Advanced Platform partner, will unveil its latest Generative AI-powered contract lifecycle management solution at ServiceNow KNOWLEDGE24 in Las Vegas.
  • SANTA CLARA, Calif., April 25, 2024 /PRNewswire/ --  Aavenir, a global AI-Powered Source-to-Pay and Contract Lifecycle Management solutions provider on ServiceNow Platform announces its participation in ServiceNow Knowledge24 event as a Gold Sponsor.
  • The 3-day annual event, held at The Venetian Expo and Convention Center, Las Vegas, Nevada, from May 7-9, 2024, will showcase Aavenir's Generative AI capabilities in Contract Management .
  • "We are excited to unveil Avy AI and our Generative AI capabilities for 'connected' contract management at KNOW24.

Northstar Announces Expected Timing of Reporting 2023 Annual Results and Details of Virtual Investor Webcast

Retrieved on: 
Thursday, April 25, 2024
Webcast, PDT, Bank statement, AB, URL, Q&A

These documents will also be available on the Company's website at www.northstarcleantech.com .

Key Points: 
  • These documents will also be available on the Company's website at www.northstarcleantech.com .
  • The Company will host a virtual investor webcast to discuss these financial results and to provide a business update to the investment community on Tuesday, April 30, 2024, at 14:00 PDT / 17:00 EDT.
  • Details are provided below.
  • Approximately two hours after the Q&A session has ended, an archived version of the webcast will be available via the webcast URL above.

Solventum Announces First Quarter 2024 Earnings Release Date and Upcoming Investor Events

Retrieved on: 
Tuesday, April 23, 2024
PDT, SOLV, EDT, Bank, Conference, Health care, Bank of America

ST. PAUL, Minn., April 23, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it will release carve-out financial results for the first quarter 2024 before the market opens on May 9, 2024.

Key Points: 
  • ST. PAUL, Minn., April 23, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it will release carve-out financial results for the first quarter 2024 before the market opens on May 9, 2024.
  • The earnings press release and accompanying materials will be available on the company's website at https://investors.solventum.com .
  • Solventum executives expect to participate in the following investor conferences:
    Bank of America Merrill Lynch Healthcare Conference 2024 in Las Vegas, Nevada on Tuesday, May 14, 2024 at 5:00 p.m. PDT / 8:00 p.m. EDT.
  • Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida on Monday, June 10, 2024 at 8:40 a.m. EDT.

National Organization for Rare Disorders (NORD) Announces 2024 Rare Impact Award Honorees, Emmy Award-Winning Journalist, Peter Alexander to Host

Retrieved on: 
Monday, April 22, 2024
Education, FDA, Haemophilia, Risk, Genetics, Policy, Legislation, Louisiana House of Representatives, Diagnosis, Community, Enzyme replacement therapy, DSM-IV codes, Universal Pictures, Usher syndrome, NBC News, Primary immunodeficiency, Metabolic disorder, Therapy, Abbey, Coagulopathy, IgA nephropathy, Hospital, Rare disease, BioMarin Pharmaceutical, Proteinuria, Alpha-mannosidosis, Regeneron Pharmaceuticals, House, Immunoglobulin A, Medicine, Biogen, Universal Studios Hollywood, HFSC, PDT, APDS, Friedreich's ataxia, Disease, Science, Patient, Caregiver, Representative, Activated, Pharmaceutical industry

"Through science and advocacy, they are transforming the lives of those impacted by rare diseases, paving the way for new possibilities in treatment and care."

Key Points: 
  • "Through science and advocacy, they are transforming the lives of those impacted by rare diseases, paving the way for new possibilities in treatment and care."
  • "Having witnessed my sister's journey, I know the challenges rare disease families face are not just physical but also emotional, mental, and financial.
  • In addition to the individual award recipients, the Rare Impact Awards are also honoring companies that have developed treatments changing the lives of those with rare diseases.
  • Regeneron Pharmaceuticals for Veopoz™: The first and only treatment indicated specifically for CHAPLE disease, a rare hereditary immune disease.

VIAVI Announces Date for Fiscal Third Quarter 2024 Financial Results

Retrieved on: 
Wednesday, April 17, 2024
PDT, EDT

CHANDLER, Ariz., April 17, 2024 /PRNewswire/ -- Viavi Solutions Inc. (VIAVI) (NASDAQ: VIAV) will announce its fiscal third quarter 2024 financial results for the period ended March 30, 2024, on Thursday, May 2, 2024, after the close of market.

Key Points: 
  • CHANDLER, Ariz., April 17, 2024 /PRNewswire/ -- Viavi Solutions Inc. (VIAVI) (NASDAQ: VIAV) will announce its fiscal third quarter 2024 financial results for the period ended March 30, 2024, on Thursday, May 2, 2024, after the close of market.
  • The Company will host an earnings call at 1:30 p.m. PDT / 4:30 p.m. EDT.
  • A live webcast of the call and the replay will be available on the VIAVI website at https://investor.viavisolutions.com .
  • The quarterly earnings press release, supplementary slides and historical financial tables will be posted under the "Quarterly Results" section.

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024

Retrieved on: 
Wednesday, April 17, 2024
PDT, EDT, Chronic pain, Webcast, Event, Internet access

The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results.

Key Points: 
  • The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results.
  • The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations .
  • The webcast can be accessed 10 minutes prior to the conference call start time.
  • For those parties that do not have internet access, the conference call can be accessed by calling one of the below telephone numbers and providing conference ID 6973396:

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Retrieved on: 
Tuesday, April 16, 2024
Fetus, AMGN, American Thoracic Society, Congress, Arthralgia, ATS, Chronic obstructive pulmonary disease, Emphysema, Pregnancy, Infection, Tezepelumab, PDT, Allergic conjunctivitis, Amgen, Research and development, Back pain, Conference, Placentalia, Vaccine, Miscarriage, Development, Ageing, Helminthiasis, Incidence, Patient, Anaphylaxis, Hypersensitivity, Rash, Pharyngitis, Birth, Asthma, Bronchitis, AstraZeneca, Excipient, Pharmaceutical industry

THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT. 

Key Points: 
  • Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17% (90% CI: −6, 36; p=0.1042).
  • Of note, more reductions were observed in a prespecified subgroup of patients with BEC ≥150 cells/μL (37% [95% CI: 7, 57]).
  • The trend in reduction was greater in a small number of subjects with BEC ≥300 cells/µL.
  • We look forward to presenting the full data set at the congress and based on these findings, we are actively planning for the Phase 3 development of tezepelumab in COPD.

FROM BUFFETT TO BENIOFF: CONTINUING A LEGACY OF COMPASSION AND GENEROSITY

Retrieved on: 
Wednesday, April 10, 2024
EBay, Volunteering, Organization, Investment, Warren Buffett, Charity, PDT, Hunger, The Power of One, Poverty, Homelessness, San Francisco Bay Area, COVID-19, SAN, Auction

SAN FRANCISCO, April 10, 2024 /PRNewswire/ -- For more than 60 years, GLIDE has been dedicated to fighting systemic injustices, creating pathways out of poverty and crisis and transforming lives. GLIDE announced today its annual Power of One Charity Lunch Auction, an exclusive lunch auction launched by Warren Buffett more than 20 years ago, will now be hosted by Salesforce Chair and CEO Marc Benioff. The one-of-a-kind event has raised $53 million to support GLIDE's transformative programs and services that lift people out of poverty, hunger, and homelessness, and advance equity through systems change. Bidding for this year's Power of One Charity Lunch Auction will be powered by longtime auction partner eBay and will open on Sunday, May 5 at 7:30 pm PDT and close on Friday, May 10 at 7:30 pm PDT. The winning bidder will enjoy a memorable lunch for eight with Benioff.

Key Points: 
  • "We are so grateful that Marc Benioff is continuing Warren Buffett's legacy of supporting San Francisco's most vulnerable," said Dr. Gina M. Fromer, GLIDE President and CEO.
  • "Warren Buffett's vision, generosity, and friendship over the last two decades has enabled GLIDE to directly improve the lives of thousands daily.
  • This legacy is in excellent hands with Marc, who has long been an outspoken champion for equality and justice in the Bay Area and worldwide."
  • Conceived by the late Susie Buffett, GLIDE launched the Power of One Charity Lunch Auction in 2000 and initially raised $25,000.

FROM BUFFETT TO BENIOFF: CONTINUING A LEGACY OF COMPASSION AND GENEROSITY

Retrieved on: 
Wednesday, April 10, 2024
EBay, Volunteering, Organization, Investment, Warren Buffett, Charity, PDT, Hunger, The Power of One, Poverty, Homelessness, San Francisco Bay Area, COVID-19, SAN, Auction

SAN FRANCISCO, April 9, 2024 /PRNewswire/ -- For more than 60 years, GLIDE has been dedicated to fighting systemic injustices, creating pathways out of poverty and crisis and transforming lives. GLIDE announced today its annual Power of One Charity Lunch Auction, an exclusive lunch auction launched by Warren Buffett more than 20 years ago, will now be hosted by Salesforce Chair and CEO Marc Benioff. The one-of-a-kind event has raised $53 million to support GLIDE's transformative programs and services that lift people out of poverty, hunger, and homelessness, and advance equity through systems change. Bidding for this year's Power of One Charity Lunch Auction will be powered by longtime auction partner eBay and will open on Sunday, May 5 at 7:30 pm PDT and close on Friday, May 10 at 7:30 pm PDT. The winning bidder will enjoy a memorable lunch for eight with Benioff.

Key Points: 
  • "We are so grateful that Marc Benioff is continuing Warren Buffett's legacy of supporting San Francisco's most vulnerable," said Dr. Gina M. Fromer, GLIDE President and CEO.
  • "Warren Buffett's vision, generosity, and friendship over the last two decades has enabled GLIDE to directly improve the lives of thousands daily.
  • This legacy is in excellent hands with Marc, who has long been an outspoken champion for equality and justice in the Bay Area and worldwide."
  • Conceived by the late Susie Buffett, GLIDE launched the Power of One Charity Lunch Auction in 2000 and initially raised $25,000.

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

Retrieved on: 
Tuesday, April 9, 2024
PDT, Chemoradiotherapy, Head, Disease, Intelligence, Patient, Neoplasm, Health care, Cancer, AI, AACR, NEC, Curie Institute (Paris), Euronext Paris, Poster, Corporation, Neck, Vaccine

Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.

Key Points: 
  • Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.
  • These data are highlighted in the AACR press conference being held today and in a poster presentation which will take place tomorrow, April 10, at 9:00 a.m. PDT.
  • Key findings of the poster include:
    All 16 patients who received TG4050 are disease free after a median 18.6-month follow-up.
  • TG4050 is now starting to show a potential benefit for head and neck cancer patients at high risk of relapse.